Cervomed Is A Clinical Stage Biotechnology Company Based In Bostonmassachusettsformed From The Merger Of Eip Pharmaincand Diffusion Pharmaceuticals Inc It Began Trading On Nasdaq Under The Ticker Symbol Crvo In August 2023The Company Specializes In Developing Therapeutics For The Central Nervous Systemcns Focusing On Neurodegenerative Diseases Such As Alzheimer Sdementia With Lewy Bodiesand Huntington S Disease Cervomed S Lead Asset Is Neflamapimoda Compound Licensed From Vertex Pharmaceuticalswhich Is Being Investigated For Various Cns Conditionsthe Company Also Has Another Asseteip200Aimed At Multiple Cns Indicationscervomed Is Actively Conducting Clinical Trialswith Neflamapimod Receiving Fda Fast Track And Orphan Drug Designations For Specific Conditionsthe Company Is Committed To Addressing Significant Market Opportunities In Neurodegenerative Diseases And Aims To Expand Its Therapeutic Reach
